Page last updated: 2024-08-23

cabergoline and Disease Exacerbation

cabergoline has been researched along with Disease Exacerbation in 16 studies

Research

Studies (16)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (6.25)	18.2507
2000's	6 (37.50)	29.6817
2010's	7 (43.75)	24.3611
2020's	2 (12.50)	2.80

Authors

Authors	Studies
Okayama, A; Sato, T; Shimatsu, A; Yamaguchi, H	1
Bronstein, MD; Greenman, Y	1
Clevenger, CV; Costa, R; Flaum, L; Gradishar, WJ; Jain, S; Kaklamani, VG; Santa-Maria, CA; Scholtens, DM	1
Cai, L; Cao, L; Guo, YH; Huang, JY; Liu, YT; Rui, WW; Shang, HB; Su, B; Tang, H; Wang, Y; Wei, YX; Wu, ZB; Wu, ZR; Yan, L; Yang, G; Yao, H; Zhang, XB; Zhang, Y; Zhao, WG	1
Akinduro, OO; Bernet, V; Chaichana, KL; De Biase, G; Donaldson, A; Izzo, A; Lu, VM; Meyer, FB; Olomu, O; Quinones-Hinojosa, A; Van Gompel, JJ; Vilanilam, G	1
Alfieri, A; Ballarino, MC; Boero, L; Chervin, A; Danilowicz, K; Diez, S; Fainstein Day, P; García-Basavilbaso, N; Glerean, M; Guitelman, M; Katz, D; Loto, MG; Mallea-Gil, MS; Manavela, M; Martinez, M; Miragaya, K; Moncet, D; Rogozinski, AS; Servidio, M; Stalldecker, G; Vitale, M	1
Cooper, O; Gertych, A; Greenman, Y; Jonas-Kimchi, T; Melmed, S; Ram, Z; Robenshtok, E; Sagiv, N; Shimon, I; Stern, N; Yaish, I; Yuan, X	1
Hide, T; Honda, Y; Kuratsu, JI; Mikami, Y; Uekawa, K; Yano, S	1
Bax, JJ; Delgado, V; Feelders, RA; Holman, ER; Kars, M; Pereira, AM; Romijn, JA; Smit, JW	1
Balasch, J; Castelo-Branco, C; Martinez, MJ	1
Berger, KB; Dodel, RC; DuChane, J; Köhne-Volland, R; Machat, O; Meyer, D; Oertel, WH; Reuther, M; Siebert, U; Smala, AM; Spottke, EA	1
Rye, DB	1
Atkinson, AB; Cooke, RS; Herron, B; Hunter, SJ; McCall, D; Sheridan, B	1
De Tommasi, A; De Tommasi, C; Guastamacchia, E; Losa, M; Luzzi, S; Resta, F; Sabbà, C; Tafaro, E; Terreni, MR; Triggiani, V	1
Ansorge, O; Fazal-Sanderson, V; Fernandez, A; Karavitaki, N; Wass, JA	1
Fariello, RG	1

Reviews

1 review(s) available for cabergoline and Disease Exacerbation

Article	Year
Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Drugs, 1998, Volume: 55 Suppl 1 Topics: Animals; Antiparkinson Agents; Area Under Curve; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2	1998

Trials

1 trial(s) available for cabergoline and Disease Exacerbation

Article	Year
A pilot study of cabergoline for the treatment of metastatic breast cancer. Breast cancer research and treatment, 2017, Volume: 165, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Cabergoline; Disease Progression; Ergolines; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pilot Projects; Retreatment; Treatment Outcome	2017

Other Studies

14 other study(ies) available for cabergoline and Disease Exacerbation

Article	Year
Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. Endocrine journal, 2020, Feb-28, Volume: 67, Issue:2 Topics: Acromegaly; Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bromocriptine; Cabergoline; Chemical and Drug Induced Liver Injury; Child; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Growth Hormone-Secreting Pituitary Adenoma; Human Growth Hormone; Humans; Hypoglycemia; Insulin-Like Growth Factor I; Japan; Male; Middle Aged; Neurosurgical Procedures; Octreotide; Peptides, Cyclic; Product Surveillance, Postmarketing; Radiotherapy; Receptors, Somatotropin; Somatostatin; Tumor Burden; Young Adult	2020
Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma. European journal of endocrinology, 2021, Aug-27, Volume: 185, Issue:4 Topics: Adenoma; Cabergoline; Chemotherapy, Adjuvant; Disease Progression; Humans; Neoplasm Recurrence, Local; Neoplasm, Residual; Neurosurgical Procedures; Patient Selection; Pituitary Neoplasms; Practice Patterns, Physicians'; Tumor Burden	2021
Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours. Nature communications, 2018, 11-05, Volume: 9, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Animals; Cabergoline; Carcinogenesis; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progression; Down-Regulation; Female; HEK293 Cells; Heterografts; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Phosphoproteins; Phosphorylation; Pituitary Neoplasms; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Long Noncoding; Up-Regulation	2018
Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure. World neurosurgery, 2019, Volume: 129 Topics: Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Sex Factors; Treatment Failure; Tumor Burden	2019
Prolactinomas: evolution after menopause. Archives of endocrinology and metabolism, 2016, Volume: 60, Issue:1 Topics: Adenoma; Adult; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Menopause; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Retrospective Studies; Treatment Outcome; Withholding Treatment	2016
Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. European journal of endocrinology, 2016, Volume: 175, Issue:1 Topics: Adenoma; Adult; Aged; Bromocriptine; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Receptors, Dopamine; Receptors, Estrogen; Treatment Outcome	2016
Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment. World neurosurgery, 2016, Volume: 95 Topics: Adolescent; Antineoplastic Agents; Cabergoline; Disease Progression; Drug Resistance, Neoplasm; Ergolines; Ganglioneuroma; Humans; Hydrocephalus; Magnetic Resonance Imaging; Male; Neoplasms, Complex and Mixed; Neuroendoscopy; Pituitary Neoplasms; Prolactinoma	2016
Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:9 Topics: Adult; Aortic Valve; Cabergoline; Calcinosis; Case-Control Studies; Cross-Sectional Studies; Disease Progression; Dopamine Agonists; Ergolines; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Time Factors; Tricuspid Valve Insufficiency	2008
Further data favouring hormonal dependency of cerebral meningiomas: evidence from a patient treated with cabergoline. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2011, Volume: 27, Issue:2 Topics: Adult; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Meningeal Neoplasms; Meningioma; Neoplasms, Hormone-Dependent	2011
Cabergoline versus levodopa monotherapy: a decision analysis. Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:8 Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Making; Disease Progression; Ergolines; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Parkinson Disease; Severity of Illness Index	2003
Relief in sight for restless legs syndrome. Neurology, 2004, Dec-28, Volume: 63, Issue:12 Topics: Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Genetic Predisposition to Disease; Humans; Restless Legs Syndrome; Treatment Outcome	2004
Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma. Clinical endocrinology, 2007, Volume: 66, Issue:1 Topics: Adult; Cabergoline; Disease Progression; Dopamine Agonists; Drug Resistance, Neoplasm; Ergolines; Female; Humans; Hyperprolactinemia; Middle Aged; Pituitary Neoplasms; Prolactinoma	2007
Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report. Minerva endocrinologica, 2007, Volume: 32, Issue:3 Topics: Adult; Cabergoline; Carcinoma; Combined Modality Therapy; Disease Progression; Dopamine Agonists; Drug Resistance; Ergolines; Fatal Outcome; Female; Humans; Octreotide; Pituitary Apoplexy; Pituitary Neoplasms; Prolactinoma; Radiosurgery; Subarachnoid Hemorrhage	2007
Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation? Pituitary, 2008, Volume: 11, Issue:3 Topics: Acromegaly; Adult; Astrocytoma; Brain Neoplasms; Cabergoline; Cranial Irradiation; Craniotomy; Disease Progression; Ergolines; Humans; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Male; Neoplasm Staging; Peptides, Cyclic; Somatostatin; Treatment Outcome; Up-Regulation	2008